Tango Therapeutics discontinues TNG348 program due to liver toxicity in phase 1/2 trial

Tango Therapeutics, Inc.

Phase 1/2 trial of TNG348, a USP1 inhibitor, terminated because of Grade 3/4 liver function abnormalities in patients on study >8 weeks.
No patient had received TNG348 in combination with olaparib; single-agent toxicity drove decision.
Cash runway extended into 2027; PRMT5 (TNG908/TNG462) and CoREST programs remain on track with clinical update expected H2 2024.
CEO Barbara Weber cited patient safety as priority; stock may react to loss of pipeline candidate.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.